Skip to main content
SpringerLink
Log in

Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The neuropharmacologic mechanisms underlying neuroleptic-induced extrapyramidal syndromes (EPS) were studied using a nonhuman primate model. Twenty-six Cebus albifrons monkeys were given weekly challenges of haloperidol (0.025 mg/kg IM), and half of the animals received the monoamine oxidase (MAO) inhibitor pargyline (5 mg/kg PO) daily for 17 consecutive days during the protocol. Pargyline caused no changes in baseline behaviors, but significantly reduced haloperidol-induced acute dystonia (AD) (-67%, P<0.002) and parkinsonism (-56%, P<0.005). The majority (8 of 13) of the experimental group had complete prevention of neuroleptic-induced EPS during cotreatment with pargyline. Behavioral scores returned to baseline levels after stopping pargyline, and did not show the further sensitization to haloperidol-induced AD that occurred in the control group. The possible mechanisms by which an MAO inhibitor might influence neuroleptic-induced AD were considered. The most likely explanation would appear to involve facilitation of striatal dopamine (DA) neurotransmission by inhibition of intra- and extraneuronal MAO, thus supporting the hypothesis that AD is due to decreased striatal DA function with secondary cholinergic hyperfunction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ayd FJ (1961) A survey of drug-induced extrapyramidal reactions. JAMA 75:1054–1060

    Google Scholar 

  • Bacopoulos NG, Redmond DE, Balau J, Roth RH (1980) Chronic haloperidol or fluphenazine: effects on dopamine metabolism in brain, cerebrospinal fluid, and plasma of Cercopithecus aethiops (vervet monkey). J Pharmacol Exp Ther 212:1–5

    Google Scholar 

  • Balsara JJ, Jadhav JH, Chandorkar AC (1979) Effects of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62:687–690

    Google Scholar 

  • Bedard P, DeLean J, LaFleur J, Larochelle L (1977) Haloperidol-induced dyskinesias in the monkey. Can J Neurol Sci 4:197–201

    Google Scholar 

  • Bowers MB, Gerbode FA (1968) Relationship of monoamine metabolites in human cerebrospinal fluid to age. Nature 219:1256–1257

    Google Scholar 

  • Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 91:104–108

    Google Scholar 

  • Burns RS, Chiveh CC, Markey S, Ebert MH, Jacobowitz D, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546–4550

    Google Scholar 

  • Campbell IC, Robinson DS, Lovenberg W, Murphy DL (1979) The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. J Neurochem 12:49–55

    Google Scholar 

  • Casey DE, Gerlach J, Christensson E (1980) Dopamine, acetylcholine, and GABA effects in acute dystonia in primates. Psychopharmacology 70:83–87

    Google Scholar 

  • Chiba K, Trevor A, Castagnol N (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Res Commun 120:574–578

    Google Scholar 

  • Cools AR, Hendricks G, Korten J (1974) The acetylcholine-dopamine balance in the basal ganglia of rhesus monkeys and its role in dynamic, dystonic, dyskinetic, and epileptoid motor activities. J Neural Transm 36:91–105

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483

    Google Scholar 

  • DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE (1976) A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 33:599–602

    Google Scholar 

  • Fowler CJ, Callingham BA, Mantle TJ, Tipton KF (1978) Monoamine oxidase A and B: a useful concept? Biochem Pharmacol 27:97–101

    Google Scholar 

  • Garrick NA, Murphy DL (1980) Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology 72:27–33

    Google Scholar 

  • Garrick NA, Redmond DE, Murphy DL (1979) Primate-rodent monoamine oxidase differences: In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: structure, function, and altered functions. Academic, New York, pp 351–359

    Google Scholar 

  • Gessa R, Tagliamonte T, Gessa GL (1972) Blockade by apomorphine of haloperidol-induced dyskinesia in schizophrenic patients. Lancet II:981–982

    Google Scholar 

  • Gunne L-M, Barany S (1976) Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology 50:237–240

    Google Scholar 

  • Karson CN (1983) Spontaneous eye-blink rates and dopaminergic systems. Brain 106:643–653

    Google Scholar 

  • Keepers GA, Casey DE (1986) Prediction of neuroleptic-induced dystonia. J Clin Psychopharmacol (in press)

  • Kolbe H, Clow A, Jenner P, Marsden CD (1981) Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release onto supersensitive postsynaptic receptors. Neurology 31:434–439

    Google Scholar 

  • Korsgaard S, Gerlach J, Christensson E (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118:245–252

    Google Scholar 

  • Kovacic B, Domino E (1984) Fluphenazine-induced acute and tardive dyskinesias in monkeys. Psychopharmacology 84:310–314

    Google Scholar 

  • Langston JW, Forno LS, Rebert CS, Irwin I (1984a) Selective nigral toxicity after systemic administration of (MPTP) in the squirrel monkey. Brain Res 292:390–394

    Google Scholar 

  • Langston JW, Irwin I, Langston EB, Forno LS (1984b) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225:1480–1482

    Google Scholar 

  • Liebman J, Neale R (1980) Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects. Psychopharmacology 68:25–29

    Google Scholar 

  • Magelund G, Gerlach J, Casey DE (1979) Neuroleptic-potentiating effect of alpha-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind crossover trial. Acta Psychiatr Scand 60:185–189

    Google Scholar 

  • Major LF, Murphy DL, Lipper S, Gordon E (1979) Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine, and serotonin in human cerebrospinal fluid. J Neurochem 32:229–231

    Google Scholar 

  • Marsden CD, Jenner P (1980) The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10:55–72

    Google Scholar 

  • McGeer E, McGeer PL (1976) Neurotransmitter metabolism in the aging brain. In: Terry RD, Gershon S (eds) Neurobiology of aging. Raven, New York, pp 389–403

    Google Scholar 

  • Meldrum BS, Anlezark G, Marsden CD (1977) Acute dystonia as an idiosyncratic response to neuroleptics in baboons. Brain 100:313–326

    Google Scholar 

  • Murphy DL, Dill RE (1972) Chemical stimulation of discrete brain loci as a method of producing dyskinesia models in primates. Exp Neurol 34:244–254

    Google Scholar 

  • Murphy DL, Kalin NH (1980) Biological and behavioral consequences of alterations in monoamine oxidase activity. Schizophr Bull 6:355–367

    Google Scholar 

  • Murphy DL, Redmond DE, Garrick NA, Baulu J (1979) Brain region differences and some characteristics of monoamine oxidase type A and B activities in the vervet monkey. Neurochem Res 4:53–62

    Google Scholar 

  • Murphy DL, Garrick NA, Aulakh CS, Cohen RM (1984) New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. J Clin Psychiatry 45:37–43

    Google Scholar 

  • Neale R, Gerhardt S, Liebman J (1984) Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys. Psychopharmacology 82:20–26

    Google Scholar 

  • Parkes JD, Bedard P, Marsden CO (1976) Chorea and torsion in parkinsonism. Lancet I:155

    Google Scholar 

  • Paulson GW (1973) Dyskinesias in monkeys. In: Huntington's chorea. Advances in Neurology, Vol. 1. Raven, New York, pp 647–650

    Google Scholar 

  • Peroutka SJ, Snyder SH (1980) Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210:88–90

    Google Scholar 

  • Porsolt R, Jalfre M (1981) Neuroleptic-induced acute dyskinesias in rhesus monkeys. Psychopharmacology 75:16–21

    Google Scholar 

  • Post RM, Goodwin FK (1975) Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients. Science 190:488–489

    Google Scholar 

  • Povlsen UJ, Noring U, Laursen AL, Korsgaard S, Gerlach J (1986) The effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in cebus monkeys. Clin Neuropsychol Pharmacol 9(1):84–90

    Google Scholar 

  • Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson's disease. J Neural Transm 38:277–301

    Google Scholar 

  • Robinson DS, Campbell IC, Walker M, Statham NJ, Lovenberg W, Murphy DL (1979) Effects of chronic monoamine oxidase inhibitor treatment on biogenic amine metabolism in rat brain. Neuropharmacology 18:771–776

    Google Scholar 

  • Robinson DS, Nies A, Davis JN, Bunney WE, Davies JM, Colburn RW, Bourne HR, Shaw DM, Coppen AJ (1972) Ageing, monoamines, and monoamine oxidase levels. Lancet I:290–291

    Google Scholar 

  • Sethy VH, Von Woert MH (1974) Modification of striatal acetylcholine concentration by dopamine receptor agonists and antagonists. Res Commun Chem Pathol Pharmacol 8:13–28

    Google Scholar 

  • Sassin JF (1975) Drug-induced dyskinesia in monkeys. In: Meldrum BS, Marsden CD (eds) Primate models of neurological disorders. Advances in Neurology, Vol. 10. Raven, New York, pp 47–54

    Google Scholar 

  • Snyder SH, Yamamura HI (1977) Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 34:236–239

    Google Scholar 

  • Snyder SH, D'Amato RJ (1986) MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. Neurology 36:250–258

    Google Scholar 

  • Stockhausen DF (1960) Clinical studies with tetrabenazine (RO1–9569). Dis Nerv Syst 21:321–328

    Google Scholar 

  • Tryding N, Tufvesson G, Nilsson S (1972) Ageing, monoamines, and monoamine oxidase levels (letter to the editor). Lancet I:4899

    Google Scholar 

  • Weiss B, Santelli S, Lusink G (1977) Movement disorders induced in monkeys by chronic haloperidol treatment. Psychopharmacology 53:289–293

    Google Scholar 

  • Youdim MBH, Riederer P, Birkmayer W, Mendlewicz J (1979) The functional activity of monoamine oxidase: the use of deprenyl in the treatment of Parkinson's disease and depressive illness. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: structure, function, and altered functions. Academic, New York, pp 477–496

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Oregon Health Sciences University, Portland, OR, USA

    R. Heintz

  2. Psychiatry Service, VA Medical Center, Portland, OR, USA

    D. E. Casey

  3. Departments of Psychiatry and Neurology, Oregon Health Sciences University, Portland, OR, USA

    D. E. Casey

  4. Department of Animal Behavior, Oregon Regional Primate Research Center, Beaverton, OR, USA

    D. E. Casey

Authors
  1. R. Heintz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. E. Casey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heintz, R., Casey, D.E. Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys. Psychopharmacology 93, 207–213 (1987). https://doi.org/10.1007/BF00179935

Download citation

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00179935

Key words

Search

Navigation